Use of Safety Monitoring Flow Sheets. Background  Flow sheets can serve as useful tools  Not required but recommended  Tailor for ease of use AND usefulness.

Slides:



Advertisements
Similar presentations
Learning objectives To understand the pathophysiologic basis for vasoactive therapies for HRS To become familiar with the diagnostic criteria for HRS To.
Advertisements

Menu Records for Self-Preparation Sites Virginia Department of Health Special Nutrition Programs 2014.
THE JOINT COMMISSION PATIENT BLOOD MANAGEMENT PERFORMANCE MEASURES
Welcome to a tour of Limb Volumes Professional 6.0 LVP6.0 is the latest version of the world famous and widely used lymphedema tracking and reporting software.
It’s All Good We All Have a Purpose Raise the Roof How Low Can You Go?
Genital Bleeding MTN 020 Training. Background  Genital Bleeding is common Includes menses Includes intermenstrual bleeding (IMB)  Determining whether.
DEVELOPMENT AND IMPLEMENTATION OF CHEMOTHERAPY ORDER TEMPLATES IN CPRS
Laboratory and Diagnostic Studies Sandra A. Mitchell, CRNP, M.Sc.N., AOCN National Institutes of Health Bethesda, MD.
Anemia Lab MHD I November 3, Case 1 A CBC is ordered on a 32-year old healthy man as part of a life-insurance policy evaluation.
MEDICATION SAFETY: Clozapine Initiation Chart Review
Clozapine Therapy Training 3/10/2015. Objectives What is Clozapine used to treat? What are the major side effects of Clozapine? Why is regular blood testing.
Lower Lights Christian Health Center Columbus, Ohio A Faith based, Non Profit Community Health Center MISSION OF LLCHC LLCHC ministers the love of Christ.
Effect of Hepatic Impairment on Sorafenib Pharmacokinetics: Results of a Multicenter, Open-Label, Single-Dose, Phase I Trial J Lettieri, A Mazzu,
Best Practices for Prevention in SBHCs Screening for High Blood Pressure.
Dose Adjustment in Renal and Hepatic Disease
Kreatinine Verklaard !? Introductie. At what level of creatinine does a 65-year-old diabetic, hypertensive white woman weighing 50 kilograms have chronic.
SPCAA Head Start & Early Head Start Mental Health and Disability.
Update on Pediatric Obesity Lessons Learned Diane Dooley MD.
Update to the Study Status Log Submission Process and Excel Tips & Tricks to Report Study Activity Accurately Vikki Rawls Fiscal & Business Analyst, USF.
MODULE B: Case Report Forms Jane Fendl & Denise Thwing April 7, Version: Final 07-Apr-2010.
Complete Blood Count.
Introduction Device infection remains a significant cause of morbidity and mortality in patients supported by mechanical assist devices. The infection.
Study Product Return Re-Supply and Re-Issue MTN-003 Study-Specific Training.
Clinical pathology: Complete Blood count
 BSA (m 2 ) = √ Ht(in) X wt (lb) 3131 Ht (cm) X wt (kg) 3600 Mosteller,RD " Simplified Calculation of Body Surface Area", N Engl J Med 1987, 317 (17):
Investigator’s Meeting
2-4. Estimated Renal Function Estimated GFR = 1.8 x (Cs) x (age) Cockcroft-Gault eq. – Estimated creatine clearance (mL/min) = (140 – age x body weight,
Red blood cell disorders / Anemia laboratory
Renal Physiology and Function Part II Renal Function Tests
Welcome. Registration complete? CQC Inspection visit Routine Responsive Themed.
objective By the end of this lesson, you will be able to :  Identify the accurate ways to measure and record height and weight.
Case 2 A 23-year old Indian young man Homozygous Beta-Thalassemia Major Diagnosed at the age of 6 months. On regular transfusion every 4 weeks since that.
Risk Factors for Linezolid-Associated Thrombocytopenia in Adult Patients Cristina Gervasoni Ospedale Luigi Sacco, Milano.
Revision for Clinical Biochemistry Lab
EPZICOM ® Virologic Response in ART-Naïve Patients with Baseline Viral Loads Above and Below 100,000c/mL Using the A5202 Endpoint K. Pappa, J. Hernandez,
Maternal clinical considerations
IMPAACT 2010 Eligibility Criteria
Maternal Toxicity Management
Clinical Case Scenarios
IMPAACT 2010 Screening Visits
IMPAACT 2010 Screening Visits
Rational Use of DXA-BMD
Summer Gupta, MSN, RN Sepsis Coordinator UCLA Health 09/13/2016
Home Health Remote Patient Monitoring For Heart Failure
Clinical Case Scenarios
Revision for Clinical Biochemistry Lab
MTN-025 Data Communiqué #1 CRF Updates.
Maternal Toxicity Management
Maternal Toxicity Management
Clinical Case Scenarios
Clinical Case Scenarios
IMPAACT 2010 Eligibility Criteria
IMPAACT 2010 Eligibility Criteria
Erythrocytapheresis.
IMPAACT 2010 Screening Visits
GYNAECOLOGY SCREENING 1
Basic laboratory testing
Basic laboratory testing
MBL: mostly benign lymphocytes, but…
Chapter 5 Normal Distribution
غدير أبو شعبان تسنيم الشلفوح سجود الجبالي
Case reports and sites activities
Streamlined Data Collection
Guidelines for Initiation of Therapy
A 24- year- old woman presented to her primary-care physician for evaluation of new tea –colored urine noticed intermittently over the past five days.
Welcome to a tour of Limb Volumes Professional 6.0
Blood Tests.
NT-proBNP calculator Age year Women Height cm Weight kg Hemoglobin
A previously healthy 43-year-old man with chronic alcoholism presented to a rural medical center with a 2-week history of confusion, fever, dyspnea, dizziness,
Fig. 5 Minimal administration of ETL is tolerable and safe in mice.
Presentation transcript:

Use of Safety Monitoring Flow Sheets

Background  Flow sheets can serve as useful tools  Not required but recommended  Tailor for ease of use AND usefulness at your site  When tailoring, consider staff roles and responsibilities AND other documentation requirements at your site

Flow Sheets  Height and weight  Vital signs  Hematology  Liver function: ALT and AST  Renal function: phosphate and creatinine

Common Elements Title Brief instructions/guidance Date and visit code Values being monitored Shading indicates “not applicable” Staff Initials

General Instructions for Use  Initiate use during screening  File for “easy access” in participant study notebook  Update at or after each visit  Continually review as part of ongoing safety monitoring  Initial and date to document reviews

Height  Why are there two rows to record height on each date?

Height  Because the protocol requires repeat measurement if a decrease of 3.8 cm or more is identified  Record NA if a second measurement is not required and therefore is not done  Severity grading is not required

Weight  Why is percentage difference from Screening Part 2 needed?

Weight  Because the severity of unintentional weight loss must be graded in terms of percent decrease 01 JAN JAN APR (M3) % 50 – 45 = 5 5 ÷ 50 = 0.10 = 10%

Vital Signs  Fever (oral temp), hypertension, and hypotension must be graded  For hypertension, grading requires repeat blood pressure measurement at the same visit

Hematology

 Hemoglobin, platelets, white blood cells, neutrophils, and lymphocytes must be graded  Hemoglobin is graded based on absolute values and difference from Screening Part 1  Neutrophils and lymphocytes are graded based on absolute counts  Although not recorded on flow sheet, abnormal differential counts should also be monitored for clinical significance

 All results should be graded  Grading is based on the site upper limit of normal (record at top of flow sheet for ease of reference) ALT and AST

Phosphate  All results should be graded  Grading is based on the site lower limit of normal (record at top of flow sheet for ease of reference)

Creatinine

 Absolute levels must be graded (based on site upper limit of normal)  Increases from baseline must be calculated to determine whether product hold is required  Creatinine clearance rate must be calculated to determine whether product hold is required

Creatinine: Relative Increase From Baseline 01 JAN APR (M3) 0.8 mg/dL0.9 mg/dL mg/dL 0.8 mg/dL mL/min87 mL/min 0.9 ÷ 0.8 = 1.1  Participant is a 23 year old, 57 kg woman, oral study product

 Questions?  Comments?  Concerns? What are your …